This editorial focuses on drug development against respiratory infectious diseases and related complications in other body systems[1][9]. It includes studies on the synergistic effect of the combination of ciprofloxacin and meropenem on multiresistant Acinetobacter baumannii, where tests have shown bactericidal effects, increased permeability of the outer membrane and inhibition of efflux pumps[2]. Further research identified a magnolol derivative 6i with antibacterial activity against MRSA (MIC 2–8 μg/mL), good plasma stability and efficacy in a murine skin abscess model comparable to vancomycin[2]. A systematic review showed that NTHi-Mcat/NTHi vaccines in patients with COPD do not reduce the risk of exacerbations or overall mortality[3]. A case study describes the successful treatment of a 78-year-old patient with severe Q fever and H1N1 with omadacycline, where tNGS confirmed the diagnosis and treatment resulted in resolution of symptoms[4]. Nebulized drugs such as budesonide with terbutaline in combination with azithromycin have shown superior clinical efficacy and safety in the treatment of mycoplasma pneumonia in children compared to azithromycin alone[5]. The review highlights the challenges of treating community-acquired pneumonia in patients with myasthenia gravis, including antibiotic selection and immunosuppressive therapy[6].